{
  "abstract": "Background The coexistence of diabetes mellitus (DM) and gastrointestinal (GI) cancers is increasingly common, yet population-level survival data for this high-risk group remain limited, particularly in Asian populations. This study aimed to characterize and compare survival outcomes across major GI cancers among patients with DM in Hong Kong.Methods We conducted a retrospective cohort study using data from the Hong Kong Hospital Authority Data Collaboration Laboratory (HADCL). Adult patients with DM newly diagnosed with GI cancers during 2000-2020 were included. GI cancers were classified into seven groups based on ICD-10 codes: esophageal (C15), gastric (C16), small intestine (C17), colorectal (C18–C21), liver (C22), biliary tract (C23–C24), and pancreatic (C25). Overall survival was estimated using the Kaplan–Meier method. Median survival time and 1-, 3-, and 5-year survival rates were calculated for each cancer group.Results Among 19,716 DM patients with GI cancers, Survival outcomes varied substantially across cancer types. Pancreatic cancer had the poorest prognosis, with a median survival of 4.1 months and 1-, 3-, and 5-year survival rates of 32.7%, 20.1%, and 18.9%, respectively. Biliary tract cancer had a median survival of 11.3 months with corresponding survival rates of 49.4%, 37.9%, and 33.5%. Esophageal cancer also showed poor outcomes with a median survival of 11.9 months and 1-, 3-, and 5-year survival rates of 49.8%, 34.7%, and 31.9%. Small intestine cancer had a median survival of 21.3 months and 1-, 3-, and 5-year survival rates of 56.0%, 47.0%, and 41.6%. Gastric cancer had a median survival of 30.4 months, with 1-, 3-, and 5-year survival rates of 63.8%, 48.5%, and 43.9%. Liver cancer demonstrated intermediate survival with a median survival of 35.2 months and 1-, 3-, and 5-year survival rates of 63.1%, 49.6%, and 42.9%. Colorectal cancer demonstrated the most favorable prognosis, with a median survival of 182.2 months and survival rates of 84.8%, 75.2%, and 69.4% at 1, 3, and 5 years, respectively.Conclusions This territory-wide study demonstrates substantial heterogeneity in survival across GI cancers among patients with DM. The markedly poor outcomes observed in pancreatic, biliary tract, and esophageal cancers highlight the need for cancer-specific management and targeted interventions in this high-risk population.",
  "authors": [
    {
      "affiliations": [
        "The Chinese University of Hong Kong, Hong Kong"
      ],
      "name": "Zhaojun Li"
    },
    {
      "affiliations": [
        "The Chinese University of Hong Kong, Hong Kong"
      ],
      "name": "Claire Chenwen Zhong"
    },
    {
      "affiliations": [
        "Peking University, China"
      ],
      "name": "Minmin Wang"
    },
    {
      "affiliations": [
        "The London School of Hygiene and Tropical Medicine, United Kingdom"
      ],
      "name": "Don Eliseo Lucero-Prisno III"
    },
    {
      "affiliations": [
        "The University of Southern California, United States"
      ],
      "name": "Mellissa Withers"
    },
    {
      "affiliations": [
        "The Chinese University of Hong Kong, Hong Kong"
      ],
      "name": "Martin Chi-Sang Wong"
    },
    {
      "affiliations": [
        "The Chinese University of Hong Kong, Hong Kong"
      ],
      "name": "Junjie Huang"
    }
  ],
  "title": "IDDF2026-ABS-0425 Survival outcomes of gastrointestinal cancers in patients with diabetes",
  "uid": "f0982d2a-8d09-5be5-95b6-5f07888937e8"
}